|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
JO3701B1
(ar)
*
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
AR102198A1
(es)
|
2014-10-09 |
2017-02-08 |
Regeneron Pharma |
Proceso para reducir partículas subvisibles en una formulación farmacéutica
|
|
TW202440904A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（二）
|
|
CN106928326B
(zh)
*
|
2015-12-31 |
2019-12-24 |
中国科学院微生物研究所 |
一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CN107298712B
(zh)
*
|
2016-04-14 |
2020-04-07 |
中国疾病预防控制中心病毒病预防控制所 |
全人源化抗中东呼吸综合征冠状病毒中和抗体
|
|
TW201815821A
(zh)
*
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
JP2019529350A
(ja)
|
2016-08-16 |
2019-10-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
混合物から個々の抗体を定量する方法
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
BR112019006689A2
(pt)
|
2016-10-25 |
2019-06-25 |
Regeneron Pharma |
métodos e sistemas para análise de dados de cromatografia
|
|
KR20180058206A
(ko)
*
|
2016-11-23 |
2018-05-31 |
에스케이케미칼 주식회사 |
중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
|
|
EP3570668A1
(en)
*
|
2017-01-19 |
2019-11-27 |
Open Monoclonal Technology, Inc. |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
KR20200010390A
(ko)
|
2017-05-22 |
2020-01-30 |
에프. 호프만-라 로슈 아게 |
치료 화합물 및 조성물, 및 이의 사용 방법
|
|
KR20250041082A
(ko)
|
2017-07-06 |
2025-03-25 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
|
KR101895228B1
(ko)
*
|
2017-08-23 |
2018-10-30 |
대한민국 |
중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
|
|
KR102798879B1
(ko)
|
2017-09-19 |
2025-04-30 |
리제너론 파아마슈티컬스, 인크. |
입자 형성을 감소시키는 방법 및 그것에 의해 형성된 조성물
|
|
US11230592B2
(en)
|
2017-09-27 |
2022-01-25 |
The Wistar Institute Of Anatomy And Biology |
DNA antibody constructs for use against middle east respiratory syndrome coronavirus
|
|
WO2019078600A1
(ko)
*
|
2017-10-19 |
2019-04-25 |
(주)에이티젠 |
중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
|
|
EP3727629A1
(en)
|
2017-12-22 |
2020-10-28 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
|
WO2019151632A1
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
JP7349998B2
(ja)
|
2018-01-31 |
2023-09-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
|
|
KR20190093107A
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
JP2021514609A
(ja)
|
2018-02-28 |
2021-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ウイルス混入物質を同定するためのシステムおよび方法
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
MY202358A
(en)
|
2018-03-19 |
2024-04-24 |
Regeneron Pharma |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11690907B2
(en)
|
2018-06-12 |
2023-07-04 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
US11696948B2
(en)
|
2018-06-12 |
2023-07-11 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
CN110616198B
(zh)
*
|
2018-06-19 |
2021-02-19 |
清华大学 |
一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗
|
|
TWI853823B
(zh)
|
2018-07-02 |
2024-09-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
KR102682192B1
(ko)
*
|
2018-08-17 |
2024-07-04 |
한림대학교 산학협력단 |
메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도
|
|
EP3774841A1
(en)
|
2018-08-27 |
2021-02-17 |
Regeneron Pharmaceuticals, Inc. |
Use of raman spectroscopy in downstream purification
|
|
CA3100038A1
(en)
|
2018-08-30 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
RU2709659C1
(ru)
*
|
2018-09-06 |
2019-12-19 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
|
|
KR102007161B1
(ko)
*
|
2018-11-07 |
2019-08-07 |
대한민국 |
메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체
|
|
BR112021009543A2
(pt)
|
2019-01-16 |
2021-08-17 |
Regeneron Pharmaceuticals, Inc. |
métodos para identificar tióis livres em um medicamento de proteína, de identificação de heterogeneidade de dissulfeto em um medicamento de proteína e para selecionar um medicamento de proteína, e, composição farmacêutica
|
|
CN113874394B
(zh)
*
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
|
US11364276B2
(en)
|
2019-03-26 |
2022-06-21 |
National Guard Health Affairs |
Antiviral peptides for treatment of the middle east respiratory syndrome
|
|
CN118064502A
(zh)
*
|
2019-04-03 |
2024-05-24 |
瑞泽恩制药公司 |
用于将抗体编码序列插入到安全港基因座中的方法和组合物
|
|
KR102213745B1
(ko)
*
|
2019-04-16 |
2021-02-09 |
주식회사 바이오앱 |
돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
|
|
SG11202110911RA
(en)
|
2019-05-13 |
2021-10-28 |
Regeneron Pharma |
Improved competitive ligand binding assays
|
|
WO2021060837A1
(en)
*
|
2019-09-23 |
2021-04-01 |
Seoul National University R&Db Foundation |
Anti-mers-cov antibody and use thereof
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
US11730793B2
(en)
|
2019-11-25 |
2023-08-22 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
WO2021150558A1
(en)
|
2020-01-21 |
2021-07-29 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
CA3163164A1
(en)
|
2020-02-10 |
2021-08-19 |
Alina Baum |
Anti-tmprss2 antibodies and antigen-binding fragments
|
|
BR112022015707A2
(pt)
*
|
2020-02-10 |
2022-09-27 |
Inst Microbiology Cas |
Antígenos de beta-coronavírus, métodos de preparação e usos dos mesmos
|
|
DK3872091T5
(da)
|
2020-02-26 |
2024-08-12 |
Vir Biotechnology Inc |
Antistoffer mod sars-cov-2
|
|
CN113321713B
(zh)
*
|
2020-02-28 |
2022-11-01 |
深圳市亚辉龙生物科技股份有限公司 |
SARS-CoV-2的重组RBD蛋白及其制备方法
|
|
MX2022011142A
(es)
*
|
2020-03-09 |
2022-12-13 |
Abcellera Biologics Inc |
Anticuerpos anti-coronavirus y metodos de uso.
|
|
US20210283243A1
(en)
*
|
2020-03-11 |
2021-09-16 |
Ibio, Inc. |
Lichenase-covid-19 based vaccine
|
|
CN115484964B
(zh)
*
|
2020-03-12 |
2024-03-15 |
S·D·卡利斯-希尔 |
冠状病毒感染和相关细胞因子毒性的治疗
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
WO2021207948A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-sars-cov-2 antibodies and uses thereof
|
|
PL4045533T3
(pl)
|
2020-03-26 |
2024-04-15 |
Vanderbilt University |
Ludzkie przeciwciała monoklonalne przeciwko ciężkiemu ostremu zespołowi oddechowemu wywołanemu koronawirusem 2 (sars-cov-2)
|
|
WO2021201679A1
(en)
|
2020-04-01 |
2021-10-07 |
Kiadis Pharma Intellectual Property B.V. |
Compositions and methods targeting coronaviruses
|
|
KR20230005850A
(ko)
*
|
2020-04-01 |
2023-01-10 |
티오제네시스 테라퓨틱스, 인크. |
베타코로나바이러스 감염의 치료를 위한 시스테아민 전구체 화합물
|
|
SG11202103404PA
(en)
|
2020-04-02 |
2021-04-29 |
Regeneron Pharma |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
WO2021216876A2
(en)
*
|
2020-04-24 |
2021-10-28 |
The Board Of Regents Of The University Of Texas System |
Antibodies to coronavirus spike protein and methods of use thereof
|
|
JP7778685B2
(ja)
*
|
2020-04-30 |
2025-12-02 |
富士フイルム富山化学株式会社 |
ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤
|
|
GB202007532D0
(en)
*
|
2020-05-20 |
2020-07-01 |
Alchemab Therapeutics Ltd |
Polypeptides
|
|
WO2021238910A1
(en)
*
|
2020-05-25 |
2021-12-02 |
Guo Bingshi |
Anti-coronavirus spike protein antibodies and uses thereof
|
|
BR112022024149A2
(pt)
*
|
2020-05-26 |
2023-02-07 |
Regeneron Pharma |
Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
|
|
CN111606981B
(zh)
*
|
2020-05-27 |
2022-02-08 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s1蛋白多肽及其应用
|
|
US11999777B2
(en)
|
2020-06-03 |
2024-06-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
|
|
US20230227539A1
(en)
*
|
2020-06-16 |
2023-07-20 |
Hifibio (Hk) Limited |
Methods and compositions related to neutralizing antibodies against human coronavirus
|
|
WO2021260075A1
(en)
*
|
2020-06-23 |
2021-12-30 |
Navigo Proteins Gmbh |
Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
|
|
WO2022019711A1
(ko)
*
|
2020-07-24 |
2022-01-27 |
(주)셀트리온 |
코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자
|
|
WO2022026807A2
(en)
*
|
2020-07-30 |
2022-02-03 |
Albert Einstein College Of Medicine |
Antibodies targeting sars-cov-2 and uses thereof
|
|
JP2023537470A
(ja)
*
|
2020-08-03 |
2023-09-01 |
ヤンセン バイオテツク，インコーポレーテツド |
ウイルス治療における多方向バイオ輸送のための材料及び方法
|
|
US20230357365A1
(en)
*
|
2020-08-07 |
2023-11-09 |
Novelgen Co., Ltd. |
Antiviral composition against coronavirus
|
|
BR112023003273A2
(pt)
|
2020-08-31 |
2023-05-02 |
Regeneron Pharma |
Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
|
|
WO2022054068A1
(en)
*
|
2020-09-14 |
2022-03-17 |
Ramot At Tel-Aviv University Ltd. |
Antibodies for the prevention, treatment and detection of coronavirus infection
|
|
CA3192706A1
(en)
*
|
2020-09-15 |
2022-03-24 |
Gregory SEMPOWSKI |
Coronavirus antibodies and uses thereof
|
|
EP4217386A4
(en)
*
|
2020-09-24 |
2025-01-15 |
The Broad Institute, Inc. |
PLATFORM FOR ENGINEERING CELL-FREE ANTIBODIES AND NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2
|
|
CN112379087B
(zh)
*
|
2020-10-21 |
2022-02-11 |
中国医学科学院医学生物学研究所 |
一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法
|
|
US12239687B2
(en)
|
2020-11-25 |
2025-03-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
KR20230121854A
(ko)
|
2020-12-17 |
2023-08-21 |
리제너론 파아마슈티컬스, 인크. |
단백질-캡슐화 마이크로겔의 제작
|
|
US11834493B2
(en)
|
2021-01-05 |
2023-12-05 |
Immunome, Inc. |
Antibody cocktail against SARS-CoV-2 spike protein
|
|
CN114716541B
(zh)
*
|
2021-01-05 |
2023-07-21 |
中国科学院分子细胞科学卓越创新中心 |
抗冠状病毒的全人广谱中和抗体76e1及其应用
|
|
AU2022209730A1
(en)
|
2021-01-20 |
2023-07-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving protein titer in cell culture
|
|
US20240101645A1
(en)
*
|
2021-01-22 |
2024-03-28 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Monoclonal antibodies against coronaviruses and uses thereof
|
|
WO2022170126A2
(en)
*
|
2021-02-05 |
2022-08-11 |
Adagio Therapeutics, Inc. |
Compounds specific to coronavirus s protein and uses thereof
|
|
WO2022182662A1
(en)
|
2021-02-23 |
2022-09-01 |
10X Genomics, Inc. |
Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest
|
|
KR20230154020A
(ko)
*
|
2021-03-02 |
2023-11-07 |
노바록 바이오테라퓨틱스 리미티드 |
클라우딘-6에 대한 항체 및 이의 용도
|
|
BR112023017442A2
(pt)
|
2021-03-03 |
2023-09-26 |
Regeneron Pharma |
Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
EP4308589A4
(en)
*
|
2021-03-15 |
2025-02-26 |
Emory University |
SARS-COV-2 ANTIBODIES AND FRAGMENTS, THERAPEUTIC USES, DIAGNOSTIC USES AND COMPOSITIONS RELATED THERETO
|
|
WO2022212654A2
(en)
*
|
2021-04-02 |
2022-10-06 |
The Scripps Research Institute |
Cross-reactive monoclonal antibodies against coronaviruses
|
|
WO2022241200A1
(en)
*
|
2021-05-14 |
2022-11-17 |
Vanderbilt University |
Cross-reactive coronavirus antibodies
|
|
EP4348234A1
(en)
|
2021-06-01 |
2024-04-10 |
Regeneron Pharmaceuticals, Inc. |
Micropchip capillary electrophoresis assays and reagents
|
|
TW202321292A
(zh)
|
2021-07-14 |
2023-06-01 |
美商再生元醫藥公司 |
抗sars-cov-2-棘醣蛋白抗體及抗原結合片段
|
|
WO2023004431A2
(en)
*
|
2021-07-23 |
2023-01-26 |
The Trustees Of Columbia University In The City Of New York |
Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
|
|
WO2023039457A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
|
|
EP4405390A1
(en)
|
2021-09-20 |
2024-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
CN116178530A
(zh)
*
|
2021-09-26 |
2023-05-30 |
上海君实生物医药科技股份有限公司 |
抗体在治疗SARS-CoV-2感染的用途
|
|
CA3230984A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Systems and methods of ph modeling and control
|
|
WO2023059803A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
|
US20240409618A1
(en)
*
|
2021-10-13 |
2024-12-12 |
The Wistar Institute Of Anatomy And Biology |
DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
|
|
IL312372A
(en)
|
2021-10-26 |
2024-06-01 |
Regeneron Pharma |
Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
WO2023178182A1
(en)
|
2022-03-16 |
2023-09-21 |
10X Genomics, Inc. |
Compositions and methods for detection and treatment of coronavirus infection
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
TW202446462A
(zh)
|
2023-02-22 |
2024-12-01 |
美商再生元醫藥公司 |
系統適用性參數及管柱老化
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
TW202535934A
(zh)
|
2023-11-02 |
2025-09-16 |
美商再生元醫藥公司 |
利用應力來降低脂酶活性的方法
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
CN119264262B
(zh)
*
|
2024-09-19 |
2025-09-02 |
中山大学 |
一种双特异性抗体及其应用
|